Recipharm AB Appoints New General Manager For Recipharm Italia S.P.A

Recipharm, the leading contract development and manufacturing organisation, has today announced that Giorgio Bruno has been appointed General Manager of Recipharm Italia S.p.A. In this role, he will serve as CEO for all of Recipharm's Italian operating companies which employ some 257 people at three sites and have revenues of €57m.

Dr Bruno has long established senior management experience from within the pharmaceutical industry, especially in the area of manufacturing. He has worked in both Italian and multinational pharmaceutical companies covering a wide range of disciplines. In particular he has had responsibility for quality and manufacturing at such companies including Parke Davis, AstraZeneca and Corden Pharma. Dr Bruno also has strong industry knowledge and has held a number of positions within Italian based industry associations. He holds a Ph. D. in Pharmaceutical Chemistry and Technology from the University of Milan.

"Commenting on the appointment, Thomas Eldered, CEO of Recipharm remarked: "I am very pleased to welcome Dr Bruno to the Recipharm team. We are very fortunate to have been able to attract such a competent and highly experienced manager to this important position and I look forward to him bringing his expertise to bear across our Italian operations for which he is now responsible."

For more information please visit www.recipharm.com or contact:

Thomas Eldered, CEO Recipharm, [email protected], + 46 8 602 52 10

Kjell Johansson, EVP COO Recipharm, [email protected], + 46 739 622 620

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: [email protected] or [email protected], Tel: +44 (0) 207 861 3019/304

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com

For media enquiries, please contact Tristan Jervis on +44 (0) 207 203 6740 or e-mail: [email protected]

Recipharm AB (publ)

Corporate identity number 556498-8425

Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03

www.recipharm.com

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.